On September 15, 2014, Gilead licensed its anti hepatitis C drugs Sovaldi and Ledipasvir to 7 drugmakers in India. The licensing deal permits the companies to manufacture and sell the highly curative 12-week course of treatment for as little as $1,000, or roughly 1% of the drug’s cost in the United States. The agreement permits the Indian based drugmakers to distribute the therapy only to the 91 low-income countries listed here:
-
AFRICA AND COASTAL AFRICA
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African Republic
Chad
Comoros
Congo Republic
Democratic Republic of the Congo
Côte d’Ivoire
Djibouti
Egypt
Eritrea
Ethiopia
Equatorial Guinea
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mauritius
Mozambique
Namibia
Niger
Nigeria
Rwanda
São Tomé and Príncipe
Senegal
Seychelles
Sierra Leone
Somalia
South Africa
South Sudan
Sudan
Swaziland
Tanzania, U. Rep. of
Togo
Uganda
Zambia
Zimbabwe
-
ASIAN AND THE PACIFIC
Bangladesh
Bhutan
Cambodia
Fiji
India
Indonesia
Kiribati
Lao, People’s Dem. Rep.
Maldives
Myanmar
Nauru
North Korea
Nepal
Pakistan
Palau
Papua New Guinea
Solomon Islands
Sri Lanka
Timor-Leste
Tonga
Tuvalu
Vanuatu
Vietnam
LATIN AMERICAN AND THE CARIBBEAN
Antigua and Barbuda
Bolivia
Cuba
Dominica
Guatemala
Guyana
Haiti
Honduras
Nicaragua
St. Vincent & the Grenadines
Suriname
MIDDLE, NEAR EAST AND CENTRAL ASIA
Afghanistan
Kyrgyzstan
Mongolia
Tajikistan
Turkmenistan
Uzbekistan